392 related articles for article (PubMed ID: 12098700)
1. Sustained loss of a neoplastic phenotype by brief inactivation of MYC.
Jain M; Arvanitis C; Chu K; Dewey W; Leonhardt E; Trinh M; Sundberg CD; Bishop JM; Felsher DW
Science; 2002 Jul; 297(5578):102-4. PubMed ID: 12098700
[TBL] [Abstract][Full Text] [Related]
2. Rehabilitation of cancer through oncogene inactivation.
Shachaf CM; Felsher DW
Trends Mol Med; 2005 Jul; 11(7):316-21. PubMed ID: 15955741
[TBL] [Abstract][Full Text] [Related]
3. Cancer therapy: switching off oncogenes.
Pompetti F; Pilla D; Giancola R
Bioessays; 2003 Feb; 25(2):104-7. PubMed ID: 12539235
[TBL] [Abstract][Full Text] [Related]
4. Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis.
Pelengaris S; Abouna S; Cheung L; Ifandi V; Zervou S; Khan M
BMC Biol; 2004 Dec; 2():26. PubMed ID: 15613240
[TBL] [Abstract][Full Text] [Related]
5. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy.
Shachaf CM; Felsher DW
Cancer Res; 2005 Jun; 65(11):4471-4. PubMed ID: 15930260
[TBL] [Abstract][Full Text] [Related]
6. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation.
Boxer RB; Jang JW; Sintasath L; Chodosh LA
Cancer Cell; 2004 Dec; 6(6):577-86. PubMed ID: 15607962
[TBL] [Abstract][Full Text] [Related]
7. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.
Shachaf CM; Kopelman AM; Arvanitis C; Karlsson A; Beer S; Mandl S; Bachmann MH; Borowsky AD; Ruebner B; Cardiff RD; Yang Q; Bishop JM; Contag CH; Felsher DW
Nature; 2004 Oct; 431(7012):1112-7. PubMed ID: 15475948
[TBL] [Abstract][Full Text] [Related]
8. Tumor dormancy and oncogene addiction.
Felsher DW
APMIS; 2008; 116(7-8):629-37. PubMed ID: 18834407
[TBL] [Abstract][Full Text] [Related]
9. Oncogene addiction: sometimes a temporary slavery.
Jonkers J; Berns A
Cancer Cell; 2004 Dec; 6(6):535-8. PubMed ID: 15607957
[TBL] [Abstract][Full Text] [Related]
10. Conditionally MYC: insights from novel transgenic models.
Arvanitis C; Felsher DW
Cancer Lett; 2005 Aug; 226(2):95-9. PubMed ID: 16039948
[TBL] [Abstract][Full Text] [Related]
11. (18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation.
Arvanitis C; Bendapudi PK; Tseng JR; Gambhir SS; Felsher DW
Cancer Biol Ther; 2008 Dec; 7(12):1947-51. PubMed ID: 18981708
[TBL] [Abstract][Full Text] [Related]
12. Is oncogene addiction angiogenesis-dependent?
Folkman J; Ryeom S
Cold Spring Harb Symp Quant Biol; 2005; 70():389-97. PubMed ID: 16869776
[TBL] [Abstract][Full Text] [Related]
13. Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in mice.
Pérez-Caro M; Gutierrez-Cianca N; González-Herrero I; López-Hernández I; Flores T; Orfao A; Sánchez-Martín M; Gutiérrez-Adán A; Pintado B; Sánchez-García I
Oncogene; 2007 Mar; 26(12):1702-13. PubMed ID: 16983340
[TBL] [Abstract][Full Text] [Related]
14. [Adenovirus mediated antisense c-myc gene on the chemotherapy sensitivity of osteosarcoma cells to cisplatin].
Yang DS; Xie XK; Ye ZM; Tao HM
Zhonghua Wai Ke Za Zhi; 2005 Jun; 43(12):799-802. PubMed ID: 16083584
[TBL] [Abstract][Full Text] [Related]
15. E1A oncogene-induced sensitization of human tumor cells to innate immune defenses and chemotherapy-induced apoptosis in vitro and in vivo.
Cook JL; Miura TA; Iklé DN; Lewis AM; Routes JM
Cancer Res; 2003 Jun; 63(12):3435-43. PubMed ID: 12810682
[TBL] [Abstract][Full Text] [Related]
16. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo.
Blyth K; Vaillant F; Hanlon L; Mackay N; Bell M; Jenkins A; Neil JC; Cameron ER
Cancer Res; 2006 Feb; 66(4):2195-201. PubMed ID: 16489021
[TBL] [Abstract][Full Text] [Related]
17. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic silencing of cell adhesion molecule 1 in different cancer progenitor cells of transgenic c-Myc and c-Raf mouse lung tumors.
Reamon-Buettner SM; Borlak J
Cancer Res; 2008 Sep; 68(18):7587-96. PubMed ID: 18794147
[TBL] [Abstract][Full Text] [Related]
19. Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation.
Cory S; Vaux DL; Strasser A; Harris AW; Adams JM
Cancer Res; 1999 Apr; 59(7 Suppl):1685s-1692s. PubMed ID: 10197581
[TBL] [Abstract][Full Text] [Related]
20. Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia.
Flores I; Murphy DJ; Swigart LB; Knies U; Evan GI
Oncogene; 2004 Aug; 23(35):5923-30. PubMed ID: 15208685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
